Insights Into Multiple Myeloma (MM)
Perspectives on current treatment practices regarding frontline therapy of MM, the evolving role of MRD testing in MM, treatment in later lines of therapy, and attitudes toward recently introduced agents
Faculty Chair
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Chair
Ariel F. Grajales-Cruz, MD
Moffitt Cancer Center, Tampa, FL, USA
Faculty Chair
Sagar Lonial, MD
Winship Cancer Institute, Emory University, Atlanta, GA, USA
Faculty Chair
Ariel Grajales-Cruz, MD
Moffitt Cancer Center, Tampa, FL, USA
Faculty Chair
Jeffrey Matous, MD
Colorado Blood Cancer Institute, Denver, CO, USA
Faculty Chair
Ajai Chari, MD
Mount Sinai, New York, NY, USA
Faculty Chair
Morie Gertz, MD
Mayo Clinic Cancer Center, Phoenix, AZ, USA
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Puerto Rico
More Information
- Philadelphia, PA
- Delaware, Massachusetts, New Jersey, New York, and Pennsylvania
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
More Information
- Virtual series
- Delaware, Massachusetts, New Jersey, New York, and Pennsylvania
More Information
- Virtual series
- West
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of MM
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies are obtained: bortezomib, carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, pomalidomide, thalidomide, melphalan, cyclophosphamide, bendamustine, panobinostat, selinexor, isatuximab, and venetoclax
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
